This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Leela Barham and Tim Wilsdon discuss the potential impact that value-based pricing (VBP) may have in the UK and the broader implications for developing international models of Health Technology Assessment (HTA). The article can be found here:
Are GLP-1 weight-loss therapies growing primarily by expanding the treatment population or by capturing share from existing obesity therapies? Obesity afflicts...
Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...
As the center of life sciences innovation increasingly shifts to China, companies must be ready for a more complex international arbitration landscape. In this...
Daniel Shack is a panelist during the session titled “Survey Says…” In recent proceedings, consumer survey evidence has been tendered. What’s it for? What’s it...
